Oriola Corp Class B · OMXHEX:ORIOLA
Oriola Corp Class B — Q3 2026 Earnings Presentation
23 slides from Oriola Corp Class B's earnings presentation, Oct 29, 2026
Slide 1: Interim Report January-September 2026
Interim Report January- September 2026 29 October 2026
Slide 2: Disclaimer
Disclaimer The following applies to this presentation, the oral presentation of the information in this presentation by Oriola Corporation (the “Company” or “Oriola”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “In
Slide 3: Agenda
Agenda 1 Q3 2026 highlights 2 Operating environment 3 Segments 4 Financial review Q&A Q3 2026 29 OCTOBER 2026 3
Slide 4: Progress on strategic priorities and core business performance
Progress on strategic priorities and core business performance • Solid business performance as we continued to strengthen profitable growth through commercial execution, operational improvements, and infrastructure development. Q3 26 • Net sales grew by 5.1%, supported by continued high volumes in s
Slide 5: Operating environment
Operating environment • In the third quarter, the value of the pharmaceutical distribution market grew in Sweden (7.8%), while growth in Finland remained low (0.5%). • Geopolitical developments continued to contribute to an uncertain operating environment, with high fuel prices and inflationary pres
Slide 6: Services segment in Q3: Strong partnerships deliver results
Services segment in Q3: Strong partnerships deliver results • Strengthened joint account planning to • Net sales grew by 3.7% to EUR 36.4 (35.1) improve value and margins over time. million supported by continued high volumes • Extended key partnerships and secured in speciality flows, including exp
Slide 7: Products segment in Q3: Focused growth plan brings positive outcome
Products segment in Q3: Focused growth plan brings positive outcome • Continued to align portfolio to growing • Net sales grew by 8.8% to EUR 16.8 (15.4) sales channels and focus on products that million supported by wholesale growth and support profitable growth. strong sales of special-licensed me
Slide 8: Continuous improvements enhance supply chain efficiency
Continuous improvements enhance supply chain efficiency • Stable operations in Finland and Sweden despite elevated inventory levels and increased capacity pressure. • Efficiency gains from transport planning, delivery accuracy improvements, route optimisation in Northern Sweden and streamlined tote
Slide 9: Strategic projects to modernise Oriola
Strategic projects to modernise Oriola, support long- term competitiveness and improve profitability Modernising Oriola’s physical and digital infrastructure is a key part of delivering the 10+10+10 roadmap to double EBITDA by 2029 and strengthen the foundation for future growth. Timeline and invest
Slide 10: Financial review
Financial review Q3 2026 29 OCTOBER 2026 10
Slide 11: Invoicing and net sales
Invoicing and net sales Invoicing EUR million Net sales EUR million +3.4% 1,054 +5.1% 1,019 50.4 53.0 7-9 2026 • Invoicing increased by 3.4% to EUR 1,053.6 (1,018.6) million. • Net sales increased by 5.1% to EUR 53.0 (50.4) million. • Net sales growth driven especially by the Products segment. Q3 25
Slide 12: EBITDA
EBITDA Adjusted EBITDA EUR million 7-9 2026 • Adjusted EBITDA margin 18.1% (19.0%). • One-off own products inventory provision of EUR 0.7 million. 25.2 25.3 • Adjusting items totalled EUR -3.5 (-2.6) million and included EUR -3.4 million ERP investment related implementation cost in Group 10.0 admin
Slide 13: Services segment
Services segment Invoicing EUR million Net sales EUR million Adjusted EBITDA EUR million +5.6% +1.7% 3,222 108.3 110.1 -0.6% 3,050 27.3 27.1 +3.3% +3.7% 35.1 36.4 +5.4% 1,006 1,039 10.1 9.6 Q3 25 Q3 26 YTD 25 YTD 26 Q3 25 Q3 26 YTD 25 YTD 26 Q3 25 Q3 26 YTD 25 YTD 26 7-9 2026 • Existing and recently
Slide 14: Products segment
Products segment Net sales EUR million Adjusted EBITDA EUR million -3.0% 50.5 49.0 +8.8% 16.8 Excl. Swedish dose 15.4 dispensing business, net sales grew by 4.6% +19.0% 4.8 Excl. Swedish dose 4.0 dispensing business, -11.2% adjusted EBITDA 1.9 1.7 was EUR 4.8 (3.8) million and adjusted EBITDA margin
Slide 15: Improved net profit YTD compared to last year
Improved net profit YTD compared to last year Net profit EUR million 15.3 2026 1-9 2026 -9.7 1-9 • EBITDA above last year mainly due to lower adjusting 5.6 items. -5.0 • Adjusting items totalled EUR -10.1 (-10.7) million and included EUR -9.4 million ERP investment related -1.6 -0.2 -1.3 implementat
Slide 16: Free cash flow
Free cash flow Free cash flow EUR million 1-9 1-9 Abs. 1-9 2026 EUR million 2026 2025 change • EBITDA above last year mainly due to lower adjusting items. EBITDA 15.3 14.5 0.8 • Increase in trade receivables has negatively impacted Adjustments 0.7 -1.4 2.1 working capital, primarily due to a reduced
Slide 17: Net debt on a low level
Net debt on a low level Net interest-bearing debt EUR million Net interest-bearing debt items Sep Sep Abs. EUR million 2026 2025 change Bank loans (syndicated bank & term) 30.0 30.0 0.0 -7 Commercial papers 19.8 17.9 1.9 Advance payment from pharmacies 11.8 10.9 0.9 -37 -37 -35 -38 Lease liabilities
Slide 18: Solid financial position
Solid financial position Gearing and equity ratio % Gearing Equity ratio 16 15 16 13 12 12 12 Sep 2026 • No major changes compared to the previous quarter. • Compared to last year, net result has improved and in 2026 free cash flow has been negative mainly due to change in the factoring programme an
Slide 19: Kronans Apotek (Swedish Pharmacy Holding)
Kronans Apotek (Swedish Pharmacy Holding) 2026 2025 Change 2026 2025 Change 2025 Key figures EUR million 7-9 7-9 % 1-9 1-9 % 1-12 Net sales 321.5 302.0 6.5 977.3 910.7 7.3 1223.1 EBITA 4.6 2.7 66.7 5.4 1.0 424.6 -4.4 EBIT 2.3 0.5 382.0 -1.5 -5.8 74.1 -45.0 Adjusted EBIT 2.3 2.1 11.7 0.1 -1.0 111.5 -
Slide 20: Outlook
Outlook In 2026, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of certain phar
Slide 21: Q3 26 Key takeaways
Q3 26 Key takeaways Solid business performance and Building the foundation for future growth. profitable growth. Outlook for 2026 reiterated: Adjusted Commercial execution and operational EBITDA expected to increase from the improvements are delivering results. previous year.
Slide 22: Our next events
Our next events 25 November 2026 Sijoittaja 2026 retail investor event 23 February 2027 Financial Statements Release 2026 Thank you for joining us today!
Slide 23: Health for life
Health for life